Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0581-0001 in Hepatic Steatosis and Suspected Steatohepatitis
NCT06891365Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Mar 2025
- Primary completion
- Oct 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0581-0001 in hepatic steatosis and steatohepatitis (2 cohorts), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events at 52 weeks. Started Mar 2025; status: recruiting.
02
Drugs
NNC0581-0001
03
Conditions
hepatic steatosissteatohepatitis
Beyond the preview
Go deeper on NCT06891365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06891365.